Mometason Aristo (Mometasone Furoate Ph. Eur.)

Mometasone furoate acts as an agonist at glucocorticoid receptors in nasal mucosal cells. The activated receptor complex suppresses the transcription of pro‑inflammatory cytokines and mediators, leading to decreased swelling, mucus production and irritation within the nose.

The specific dosing regimen for Mometason Aristo is determined by the prescribing clinician based on the patient’s age, severity of symptoms and treatment response. Healthcare professionals follow the product label and local prescribing guidelines to set the appropriate number of sprays per day.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometason Aristo contains mometasone furoate, which is considered a high‑potency nasal corticosteroid with a favorable safety profile when used as directed. Compared with agents such as fluticasone propionate, mometasone often requires fewer daily sprays to achieve similar symptom control, though individual response may vary.

Store the nasal spray at room temperature, below 25 °C, in its original packaging. Keep the device away from moisture, direct sunlight and heat sources. Do not freeze the product, and ensure the cap is tightly closed when not in use.

Shake the bottle gently, prime the spray if it is the first use, then tilt the head slightly forward. Insert the tip into one nostril, close the opposite nostril with a finger, and press the actuator to deliver the prescribed number of sprays. Breathe in gently through the nose and repeat in the other nostril if required.

Serious adverse events, although rare, include nasal septal perforation, cataracts or glaucoma from prolonged use, severe allergic reactions such as anaphylaxis, and adrenal suppression when high doses are used over an extended period. Patients should seek medical attention if they notice unusual bleeding, vision changes or systemic symptoms.

Mometason Aristo should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active nasal infections, recent nasal surgery or trauma, and in those for whom systemic corticosteroid therapy is contraindicated without medical supervision.